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1. Introduction 
Vitiligo is an acquired, progressive depigmenting disorder of the skin and mucous 
membranes in which melanocytes in affected skin are selectively destroyed. Theories 
regarding the mechanism of melanocyte destruction include autoimmune, cytotoxic, 
oxidative, and neural mechanisms. Vitiligo affects 0.5-2% of the world's population and the 
usual age of onset is in the third decade of life. 
Photochemotherapy, along with phototherapy and topical therapy, are the most commonly 
utilized and effective vitiligo treatment modalities. Photochemotherapy for the treatment of 
vitiligo was historically used in ancient India and Egypt, where Hindus and Egyptians 
applied psoralen-containing plant extracts to depigmented vitiligo lesions where were then 
exposed to sunlight. These plants were found to be Ammi majus and Psoralen corylefolia, 
which contain 8-methoxypsoralen (8-MOP) and 5-methoxypsoralen (5-MOP). 
Phototherapy has been shown in many studies to induce effective repigmentation in more 
than 70% of patients with early and/or localized disease. Narrow-band ultraviolet B 
radiation (NB-UVB) with an emission spectrum of 310-312 nanometers (nm) is a safe 
treatment modality that is often used two to three times weekly as monotherapy, or 
combined with topical steroids. The treatment is safe in children, pregnant women and 
lactating mothers, and has minimal adverse effects (xerosis, pruritus, skin aging, and 
tanning). The risk of skin cancer is minimal even with multiple treatments although there is 
a greater risk of phototoxicity with depigmented skin. NB-UVB has also been used in 
combination with antioxidants such as vitamin E. 
Photochemotherapy involves the usage of psoralens combined with natural sunlight or 
UV light, usually ultraviolet A radiation (PUVA). 8-MOP or 5-MOP can be applied 
topically or used orally, followed by light exposure. Psoralens may not be used in 
pregnancy and there is a need for photoprotection following their use; there is as well a 
higher risk of burns, eye injury, and cutaneous malignancy than NB-UVB that may limit 
their cumulative usage. A 10-year retrospective study showed that PUVA is only 
moderately effective in widespread vitiligo (Kwok et al, 2002). Another small study from 
India successfully combined PUVA with a keratinocyte-melanocyte graft technique for 
stable vitiligo (Kachhawa et al, 2008). 
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Head-to-head comparison studies using NB-UVB and PUVA found both to be effective 
therapies – however, NB-UVB has been shown to induce even more stable repigmentation, 
is more convenient, and has fewer adverse effects when compared to PUVA. 
2. Ultraviolet B phototherapy 
Ultraviolet B (UVB) phototherapy is one of the most common vitiligo treatments used in the 
world today, and has evolved from the use of broadband ultraviolet B (BB-UVB) lamps to 
narrow-band ultraviolet B (NB-UVB) machines (Figure 1) with an emission spectrum of 310-
315 nm (e.g. Philips TL-01). Vitiligo was the second most frequently treated disease by NB-
UVB reported in a review published from a major U.S. phototherapy referral centre. 
 
 
Fig. 1. A Narrowband UVB body box 
UVB therapeutic modalities remain the mainstay of treatment for vitiligo due to its 
simplicity, safety and efficacy – a meta-analysis showed that it was the safest and most 
effective treatment for generalized vitiligo, with fewer adverse effects compared to psoralen 
and ultraviolet A (PUVA) therapy (Ngoo et al, 1996). Sixty-three studies were found on 
therapies for localized vitiligo. Among randomized controlled trials on localized vitiligo, the 
pooled odds ratio vs. placebo was significant for topical class 3 corticosteroids (14.32; 95% 
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confidence interval [CI], 2.45-83.72). Topical class 3 and class 4 corticosteroids carried the 
highest mean success rates (56% [95% CI, 50%-62%] and 55% [95% CI, 49%-61%], 
respectively). Side effects were reported mostly with topical psoralen and intralesional and 
class 4 corticosteroids. In randomized controlled trials on generalized vitiligo, the odds ratio 
vs. placebo was significant for oral methoxsalen plus sunlight (23.37; 95% CI, 1.33-409.93), 
oral psoralen plus sunlight (19.87; 95% CI, 2.37-166.32), and oral trioxsalen plus sunlight 
(3.75; 95% CI, 1.24-11.29). In this series, the highest mean success rates were achieved with 
NB-UVB (63%; 95% CI, 50%-76%), BB-UVB (57%; 95% CI, 29%-82%), and oral methoxsalen 
plus UVA therapy (51%; 95% CI, 46%-56%). Oral methoxsalen plus UVA was associated 
with the highest rates of side effects. No side effects were reported with UVB therapy.  
Critical reviews and guidelines recommend that UVB light be the primary phototherapy 
option for vitiligo, especially for generalized disease. A retrospective study done at a major 
referral centre in the United States administered NB-UVB phototherapy as monotherapy 
three times a week (Scherschun et al, 2001). The starting dose was 280 mJ/cm2, with 15% 
dose increments at each subsequent treatment. This treatment protocol resulted in rapid 
repigmentation in many patients, including those with skin phototypes IV and V.  
Vitiliginous areas are considered to have a type 1 Fitzpatrick response to UV light. 
Treatments are usually 2-3 times weekly with initiation of dose at 50-70% of the average 
minimal erythema dose (MED) for NB-UVB treatment for type 1 skin (about 400 mJ/cm2). 
The minimal erythema dose is the minimum dosage of UVB that produces just perceptible 
redness 24 hours after exposure. Patients should be referred to a dermatologist for UV 
radiation therapy. A total of 75 to 150 treatments (e.g. three times a week for 6 to 12 months) 
may be necessary. The course of therapy is usually much longer compared to inflammatory 
skin disorders such as atopic dermatitis and psoriasis, and the treatment course may last for 
years as long as there is continued gradual improvement and follicular repigmentation. 
However, the benefits of the usage of MED compared with fixed starting doses remains 
controversial. Fixed starting doses based on type 1 Fitzpatrick skin phototype allow an 
easier and more convenient means of initiating phototherapy, but do not take into account 
racial variations in MED. Also, many centres propose a lower maximum dose for NB-UVB 
in vitiligo compared to other inflammatory disorders (2 J/cm2 for vitiligo compared to 5 
J/cm2 for psoriasis in our phototherapy unit). 
NB-UVB has certain limitations. Lesions in acral sites are less likely to respond well to 
treatment than lesions on the face, trunk, or limbs. Segmental vitiligo is also less responsive 
to treatment. Long-standing lesions may also exhibit a lower rate of success in some cases. 
Combination therapy with topical corticosteroids and NB-UVB is both effective and safe. 
NB-UVB has been used in combination with topical calcineurin inhibitors, and most studies 
show better improvement and repigmentation compared to NB-UVB monotherapy. Sixty-
eight patients with vitiligo enrolled in a randomized, double-blind, placebo-controlled study 
(Esfandiarpour et al, 2009) in which patients were randomized into two groups: NB-UVB 
plus pimecrolimus or NB-UVB plus placebo, both for three months. NB-UVB three times a 
week was initiated at 280 mJ/cm2, with 15% increments for each subsequent treatment until 
erythema was reported or a maximum of 800 mJ/cm2 was achieved. At baseline, 6 weeks, 
and 12 weeks after commencement of therapy, vitiliginous patches were measured. No 
significant side effects were reported except self-limited erythema and pruritus. After 12 
weeks of treatment, repigmentation of facial lesions was greater in patients treated with 
combined pimecrolimus and NB-UVB compared with the placebo plus NB-UVB group (64.3 
vs. 25.1%, p < 0.05%). There was no statistically significant difference in the repigmentation 
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rate between the two groups on other body areas. This study showed that on the face, NB-
UVB works better if combined with pimecrolimus 1% cream rather than when used alone. 
Another prospective single-blind study (Majid I 2010) was performed on 80 patients with 
generalized vitiligo over 12 years of age who had symmetrically distributed vitiligo lesions 
on the face, trunk or limbs. The patients applied topical tacrolimus 0.1% ointment twice 
daily on selected symmetrically distributed lesions on the left side of the body. No topical 
agent was applied on the corresponding lesions on the right. The patients also received 
whole-body NB-UVB exposure three times every week on non-consecutive days according 
to a set protocol. Lesions selected for the comparison analysis were photographed serially 
and assessed by a single-blinded observer for the extent of repigmentation achieved. The 
extent of repigmentation achieved was calculated on the basis of VASI (Vitiligo Area 
Scoring Index) scoring. The VASI score is a composite estimate of the overall area of vitiligo 
patches at baseline and the degree of macular repigmentation within these patches over 
time, ranging from 0-100%. The time taken until initial repigmentation, as well as overall 
repigmentation achieved, and adverse effects were noted and compared between 
corresponding lesions on each side. Seventy-four patients with 234 symmetrical vitiligo 
lesions were available for comparison analysis at the end of the study period. The mean 
repigmentation achieved on the left-sided study lesions was approximately 71% (VASI score 
of 4.0) as compared to 60.5% on the symmetrically distributed right-sided lesions (VASI 
score of 3.4). Moreover, the repigmentation started earlier on the lesions on left side than on 
the right-side. No significant adverse events were reported with combination treatment. In 
this study, addition of topical tacrolimus increased the extent of overall repigmentation 
achieved with NB-UVB therapy in vitiligo and also reduced the cumulative NB-UVB dose 
needed to achieve a therapeutic benefit in affected patients. 
NB-UVB treatment was given to 24 patients with generalized vitiligo three times weekly in a 
study from Turkey (Goktas et al, 2006). Topical calcipotriol cream was only applied to the 
lesions located on the right side of the body and treatment was continued for 6 months. 
Treatment efficacy was evaluated by determining the average response rates of the lesions 
at 3-month intervals. The average response rates of patients receiving combination of NB-
UVB plus calcipotriol and NB-UVB alone were 51 ±/- 19.6% and 39 ±/- 18.9%, respectively. 
The median cumulative UVB dose and number of UVB exposures for initial repigmentation 
were 6345 mJ/cm2 (2,930-30,980 mJ/cm2) and 18 mJ/cm2 (12-67 mJ/cm2) for the 
combination therapy, and 8867.5 mJ/cm2 (2,500-30,980 mJ/cm2) and 24 mJ/cm2 (15-67 
mJ/cm2) for the NB-UVB therapy, respectively. These findings indicated that concurrent 
topical calcipotriol potentiates the efficacy of NB-UVB in the treatment of vitiligo. This 
combination not only provided earlier pigmentation with lower total UVB dosage and less 
adverse UVB effects, but also reduced the duration and cost of treatment. 
3. Psoralen with ultraviolet A (PUVA) therapy 
Vitiligo was the first described indication for psoralen with ultraviolet A (PUVA) treatment 
(Parrish et al, 1976) PUVA (Figure 2) is less used now since NB-UVB has been described as a 
safe and effective alternative (Bhatnagar et al, 2007). Psoralens are phototoxic compounds 
that interact with various components of cells and absorb photons to produce 
photochemical reactions altering the function of cellular constituents – they may be 
consumed orally or applied topically to the skin, in combination with long-wave ultraviolet 
A (UVA) radiation. For topical application, the patient may bathe in a dilute methoxsalen 
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solution or have the solution directly applied to affected areas. Psoralens may not be used in 
pregnancy and there is a higher risk of burns, cutaneous malignancy and eye injury. 
 
 
Fig. 2. A targeted UVA light source for PUVA therapy 
Patients are treated as Fitzpatrick skin type I individuals and the therapeutic objective is to 
maintain minimal light pink reactions in patches of depigmented skin. About 100-200 
exposures are required to produce maximal repigmentation and about 70% of patients 
respond. Sessions are usually 2-3 times weekly. Guidelines for psoralen administration and 
PUVA protocols for vitiligo are suggested below in Table 1 and Table 2. A comparison of 
PUVA and NBUVB for the treatment of vitiligo can be found in Table 3. 
Concurrent use of topical corticosteroids has been shown to enhance the response to 
PUVA therapy. There have been a number of recent publications combining topical 
vitamin D analogues with PUVA therapy which show a beneficial synergistic effect, but 
more studies are required.  
A placebo-controlled double-blind study (Ermis et al, 2001) was done in Turkey to 
investigate whether the effectiveness of PUVA treatment could be enhanced by combination 
with topical calcipotriol. Thirty-five patients with generalized vitiligo enrolled in the study. 
Symmetrical lesions of similar dimensions and with no spontaneous repigmentation on 
arms, legs or trunk were selected as reference lesions. In this randomized left-right 
comparison study, calcipotriol cream or placebo was applied to the reference lesions an 
hour before PUVA treatment (oral 8-MOP and conventional UVA units) twice weekly. 
Patients were examined at weekly intervals. The mean number of sessions and the 
cumulative UVA dosage for initial and complete repigmentation were calculated for twenty-
seven patients. The mean cumulative UVA dose and number of UVA exposures for initial 
repigmentation were 52.52 ± 6.10 J/cm2 and 9.33 ± 0.65 on the calcipotriol side, and 78.20 ± 
7.88 J/cm2 and 12.00 ± 0.81 on the placebo side, respectively (P < 0.001). For complete 
repigmentation, respective values were 232.79 ± 14.97 J/cm2 and 27.40 ± 1.47 on the 
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calcipotriol side and 259.93 ± 13.71 J/cm2 and 30.07 ± 1.34 on the placebo side (P = 0.001). 
Treatment with calcipotriol and PUVA resulted in significantly higher percentages of 
repigmentation for both initial (81%) and complete pigmentation (63%), compared with 
placebo and PUVA (7% and 15%, respectively). These results showed that concurrent topical 
calcipotriol potentiates the efficacy of PUVA in the treatment of vitiligo, and that this 
combination achieved earlier pigmentation with a lower total UVA dosage. 
 
Oral 8-Methoxypsoralen (8-
MOP) 
8-MOP is taken 2 hours before treatment, at a dose of 
25 mg/m2 (Ibbotson et al 2001). The body surface area 
is calculated using a normogram. Basing the dose on 
body surface area is preferable to basing the dose only 
on body weight. 
Oral 5-Methoxypsoralen (5-
MOP) 
5-MOP is taken 3 hours before treatment at a dose of 
50 mg/m2. 
Bath PUVA (Halpern et al 2000) 
30 mls of 8-MOP 1.2% solution is added to 100 mls of 
water (=3.6 mg/L at 37 °C), and the patient is immersed 
for 15 minutes. UVA exposure is given immediately. 
Patients do not need to shower afterwards but should 
have sunscreen applied to any areas that will be 
exposed to sunshine in the next 4 hours. 
Hand-Foot Immersion PUVA 
(Halpern et al 2000) 
1.3 mls of 8-MOP 1.2% solution is added to 4 litres of 
water (3.9 mg/L at 37 °C) and the patient’s hands or 
feet are immersed for 15 minutes. UVA exposure is 
ideally given 30 minutes afterwards but can be given 
immediately. The hands / feet need not be washed 
afterwards, but should have sunscreen applied if they 
will be subsequently exposed to sunshine in the next 
few hours. 
Gel PUVA (Halpern et al 2000) 
A thin layer of 0.005% gel is applied to the diseased 
area using a gloved hand. UVA exposure is given 30 
minutes later. 
Table 1. Psoralen Administration 
Psoralen and solar ultraviolet A (PUVAsol) involves the exposure of the patient to sunlight 
after administration of oral or topical psoralen. A study (Pathak et al 1984) compared 
different psoralen compounds, doses and combinations, combined with exposure to 
sunlight. There was considerable regional variation in response, with the face showing the 
best response and the acral areas the worst response. Approximately 45% of participants 
treated with the combination of 8-methoxypsoralen (8-MOP) and trimethylpsoralen (TMP) 
achieved full repigmentation of the head and nearly 60% achieved 75 to 100% 
repigmentation of the head and neck, which was statistically significant when compared to 
placebo. However, 49% of all participants reported side effects including nausea, pruritus, 
dizziness, headaches, eye discomfort and gastrointestinal symptoms, with the rate of 
complications highest in the group which used 8-MOP and TMP in combination. Khalid et 
al (1995) showed that clobetasol propionate was significantly better than PUVASOL at 
achieving at least 75% repigmentation in vitiligo patients (RR 4.70 95%CI 1.14 to 19.39). 
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Siddiqui et al (1994) examined the effectiveness of a combination of oral L-phenylalanine (L-
Phe) and UVA in an open trial and a small double-blind trial, which showed equivocal 
results. Phenylalanine is an amino acid that is the precursor of tyrosine, which is required 
for melanin pigment synthesis. Oral L-Phe loading resulted in peak plasma levels of L-Phe 
after 30-60 minutes and a slight increase in the plasma tyrosine level. Response to L-Phe 
plus UVA irradiation was positive, and various grades of repigmentation not exceeding 77% 
in the open and 60% in the blind trial were observed. An increased L-Phe dose resulted in 
increased L-Phe plasma levels but not in improved clinical results. The optimal L-Phe dose 
appeared to be lower than 50 milligrams/kilograms/day. 
 
 Frequency of 
Treatment 
Initial 
Dose 
Incremental Doses 
Maximum 
single dose 
Oral 
PUVA 
Twice a 
week 
0.5 
J/cm2 
0.25 J/cm2 increase at each visit 
until maximum dose reached. 
If erythema develops, omit 
treatment until settled and reduce 
to the previous dose, then use 
increments of 0.1-0.25 J/cm2 if no 
erythema 
5 J/cm2 
Bath 
PUVA 
Twice a 
week 
0.05 
J/cm2 to 
face 
0.1 
J/cm2 to 
other 
sites 
0.05 J/cm2 increase at each visit 
until maximum dose reached. 
If erythema develops, omit 
treatment until settled and reduce 
to the previous dose, then use 
increments of 0.02-0.05 J/cm2 if no 
erythema 
1 J/cm2 
Gel 
PUVA 
Twice a 
week 
0.5 
J/cm2 
0.25 J/cm2 increase at each visit 
until maximum dose reached. 
If erythema develops, omit 
treatment until settled and reduce 
to the previous dose, then use 
increments of 0.1-0.25 J/cm2 if no 
erythema 
1 J/cm2 
 
Table 2. PUVA protocols for vitiligo 
Camacho et al (2002) conducted an open trial on 70 patients with active vitiligo, where they 
were treated with oral and topical phenylalanine, clobetasol cream at night, sunlight in the 
spring and summer and UVA phototherapy in autumn and winter. Nearly 69% of patients 
achieved an improvement of 75% or more, but the improvement was only modest in 
patients with focal and segmental vitiligo.  
PUVA has also been combined effectively with a keratinocyte-melanocyte graft technique 
for stable vitiligo in a study from India (Kachhawa et al 2008). This autologous, non-
cultured, non-trypsinized, melanocyte plus keratinocyte grafting technique is a new and 
simple method of vitiligo surgery. In the trial, eighteen vitiligo patches underwent this 
procedure. The upper layer of epidermis was removed by superficial dermabrasion using a 
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dermabrader micromotor until the epidermis appeared wet and shiny. Then, antibiotic 
ointment was applied and dermabrasion was continued until the whitish area of the upper 
dermis was apparent. The paste-like material (ointment with entangled epidermal particles) 
was collected and spread over the dermabraded recipient site. Pigmentation usually started 
at 4-6 weeks, and then PUVA therapy was initiated. Complete uniform pigmentation took 
16-20 weeks. For smaller vitiligo patches this method gives cosmetically acceptable results. It 
is fairly easy to perform and does not require specific laboratory setup. 
 
 NB-UVB PUVA 
Ease of 
Administration 
Simple, no prior preparation 
required 
Requires topical / bath 
application or consumption 
of psoralen. 
PUVASOL allows patient 
to apply topical meladinine 
paint at home, followed by 
self-exposure to ambient 
sunlight. 
Targeted therapy 
available for 
localized vitiligo? 
Yes (Multiclear, Excimer lamp etc) Yes 
Efficacy 
Both are equally effective for vitiligo. Acral and periorificial 
areas are more resistant to phototherapy. 
A meta-analysis (Ngoo et al, 1996) showed that NB-UVB is the 
safest and most effective treatment for generalized vitiligo, with 
fewer adverse effects compared to psoralen and ultraviolet A 
(PUVA) therapy. 
Adverse Effects 
Sunburn, itch, tanning and skin 
ageing. Safe in pregnancy. 
Adverse effects related to 
photosensitivity from 
psoralen administration – 
need for sun protection and 
sun avoidance, including 
eye protection for oral 
PUVA (risk of cataracts). 
Oral PUVA can cause 
nausea and vomiting and 
its safety has not been 
established during 
pregnancy. 
Long-term safety 
Minimal skin cancer risk even 
with multiple treatments. 
Increased risk of non-
melanoma skin cancer and 
melanoma with prolonged 
treatment, especially in 
Caucasian skin. 
Table 3. Comparison between NB-UVB and PUVA 
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There has been a concern regarding the potential carcinogenicity of prolonged PUVA 
therapy, especially the increased incidence of non-melanoma skin cancer and malignant 
melanoma. Information from 4799 Swedish patients (2343 men, 2456 women) who had 
received PUVA between 1974 and 1985 was linked to the compulsory Swedish Cancer 
Registry in order to identify individuals with cancer (Lindelöf B et al 1999). The average 
follow-up period was 15.9 years for men and 16.2 for women. The authors did not find any 
increased risk for malignant melanoma in their total cohort of 4799 patients treated with 
PUVA or in a subcohort comprising 1867 patients followed for 15-21 years. For cutaneous 
SCC there was an increase in the risk: the relative risk was 5.6 (95% confidence interval, CI 4. 
4-7.1) for men and 3.6 (95% CI 2.1-5.8) for women.  
However, the majority of research demonstrating an increased incidence of skin cancer 
with psoralen plus ultraviolet A (PUVA) therapy had mainly reflected the Caucasian 
experience. A study (Murase JE et al 2005) was done of 4,294 long-term PUVA patients in 
Japan, Korea, Thailand, Egypt, and Tunisia with a follow-up period of at least 5 years. The 
relative risk of PUVA patients developing non-melanoma skin cancer relative to general 
dermatology outpatients was 0.86 [CI 0.36-1.35]. The study showed that there does not 
appear to be an increased risk of nonmelanoma skin cancer with long-term PUVA therapy 
in Asian and Arabian-African populations. Thus, in phototherapy risk assessment, it is 
important to consider the patient's skin phototype and the potential protection that more 
pigmented skin may confer. 
4. Guidance from the British Association of Dermatologists guidelines and 
the Cochrane review 
The British Association of Dermatologists (BAD) published clinical guidelines on the 
management of vitiligo (2008) that recommend that NB-UVB phototherapy (or PUVA) 
should be considered only in patients who cannot be adequately managed with conservative 
topical treatments, have widespread disease, or have localized disease significantly 
impacting quality of life.  
For non-segmental vitiligo, NB-UVB is preferred to PUVA because of greater efficacy. The 
BAD also recommends an arbitrary limit of 200 treatments with NBUVB for patients with 
skin types I–III, and 150 treatments with PUVA for patients with skin types I–III. This is in 
view of the greater susceptibility of depigmented skin to sunburn and photodamage due to 
absence of melanin. 
A Cochrane review on the management of vitiligo (2006, updated in 2010) showed limited-
to-moderate evidence for various types and regimens of phototherapy (UVA and UVB) used 
alone or in combination with psoralens, calcipotriol, folic acid and vitamin B12, oral L-
phenylalanine and topical pseudocatalase. Topical khellin combined with UVA is 
commonly used throughout the world but there is a lack of evidence of its benefit. This is 
also the case for topical tacrolimus and topical calcipotriol used in conjunction with 
ultraviolet light, oral Ginkgo biloba, and thin split-thickness grafts. The reviewers 
recommended that more randomized controlled trials are needed to fully establish the 
efficacy and safety of widely used interventions such as steroids, photochemotherapy using 
PUVA or khellin and NB-UVB monotherapy. In the future, these should also incorporate 
patient-centred outcomes such as quality of life indices. 
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5. Conclusion 
Conventional therapies for vitiligo require months to years of treatment and sometimes 
result in disappointing outcomes, particularly in difficult areas in the extremities. Thus far, 
NBUVB has remained as one of the most effective and safe treatments for vitiligo and the 
options of targeted phototherapy and combinations with various topical modalities provide 
additional choices in the dermatologist’s armamentarium. PUVA therapy has also been 
clearly shown to be efficacious but is associated with a higher risk of the adverse effects due 
to psoralen administration, and an increased risk of skin cancer especially in Caucasian skin. 
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